Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Inclusion Criteria: * HIV positive. Documentation of HIV-1 infection by means of any one of the following: 1) Documentation of HIV diagnosis in the medical record by a licensed health care provider; 2) Documentation of receipt of ART by a licensed health care provider (receipt of at least two agents is required); 3) HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating \>1000 RNA copies/mL; or, 4) Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay. * Biopsy-proven HSIL at baseline * At least one focus of HSIL must be identified that is not within a condyloma that may be treated after enrollment into the study * For females, documentation that the participant is being followed for cervical cytology (if having a cervix) and/or HPV testing per current ASCCP guidelines, and visual examination of the vulva, vagina, and cervix to rule out cancer/suspicion for cancer within 12 months prior to enrollment * Eastern Cooperative Oncology Group (ECOG) performance status \<= 1 (Karnofsky \>= 70%) * Life expectancy of greater than 5 years * Absolute neutrophil count: \>= 750/mm\^3 * Platelets: \>= 75,000/mm\^3 * Hemoglobin \>= 9.0 g/dL * Women of childbearing potential must have a negative urine pregnancy test within 7 days of initiating study treatment if they have been randomized to the treatment arm; all women …